Results 251 to 260 of about 67,445 (310)
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine+10 more
wiley +1 more source
Correlation of Biological Clock with General and Dental Health
Rishabh Bhanot+6 more
openalex +1 more source
A Novel Framework for the Design of Minimized Epigenetic Clocks Using the Analysis of DNA Methylation Heterogeneity. [PDF]
Romanov SE+15 more
europepmc +1 more source
Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte+10 more
wiley +1 more source
Evolutionary mechanisms of circadian clocks
Rodrigo Guillermo+2 more
doaj +1 more source
Causal impact of genetically-determined fish and fish oil intake on epigenetic age acceleration and related serum markers. [PDF]
Fabian P+4 more
europepmc +1 more source
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song+11 more
wiley +1 more source
Methylation-based biological age and cardiotoxicity risk in breast cancer patients treated with trastuzumab. [PDF]
Mammadova J+12 more
europepmc +1 more source
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source